Literature DB >> 19825956

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.

Rezaul Karim1, Ekaterina S Jordanova, Sytse J Piersma, Gemma G Kenter, Lieping Chen, Judith M Boer, Cornelis J M Melief, Sjoerd H van der Burg.   

Abstract

PURPOSE: The interaction between programmed cell death 1 (PD-1), expressed by activated effector or regulatory T cells, and B7-H1 (PD-L1) and B7-DC (PD-L2) results in the inhibition of T-cell function. The aim of this study was to determine B7-H1, B7-DC, and PD-1 expression in cervical carcinoma. EXPERIMENTAL
DESIGN: A tissue microarray of a well-defined group of 115 patients was stained with antibodies against B7-H1 and B7-DC. Three-color fluorescent immunohistochemistry was used to study the number and phenotype of tumor-infiltrating T cells expressing PD-1. Additional analyses consisted of in vitro T-cell suppression assays.
RESULTS: B7-H1 was expressed in 19%, and B7-DC was expressed by 29% of the 115 tumors. PD-1 was expressed by more than half of both the infiltrating CD8+ T cells and CD4+Foxp3+ T cells, irrespective of B7-H1 or B7-DC expression by tumors. The expression of B7-H1 did not show a direct impact on patient survival. However, subgroup analysis revealed that patients with a relative excess of infiltrating regulatory T cells displayed a better survival when the tumor was B7-H1 positive (P = 0.033). Additional studies showed that the presence of B7-H1 during the activation of CD4+Foxp3+ regulatory T cells impaired their suppressive function in a functional in vitro assay.
CONCLUSIONS: B7-H1 is expressed on only a minority of cervical cancers and does not influence the survival of patients with cervical cancer. PD-1 is expressed by a vast number of infiltrating CD8 T cells, suggesting that blocking of PD-1 could have therapeutic potential in cervical cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19825956     DOI: 10.1158/1078-0432.CCR-09-1652

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  111 in total

1.  Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs.

Authors:  Youngmi Kim; Hyunmi Park; Deokbum Park; Yun-Sil Lee; Jongseon Choe; Jang-Hee Hahn; Hansoo Lee; Young-Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 2.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

3.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

4.  Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.

Authors:  Elaine Bigelow; Katherine M Bever; Haiying Xu; Allison Yager; Annie Wu; Janis Taube; Lieping Chen; Elizabeth M Jaffee; Robert A Anders; Lei Zheng
Journal:  J Vis Exp       Date:  2013-01-03       Impact factor: 1.355

5.  Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue.

Authors:  Enoc M Cortés-Malagón; José Bonilla-Delgado; José Díaz-Chávez; Alfredo Hidalgo-Miranda; Sandra Romero-Cordoba; Aykut Uren; Haydar Celik; Matthew McCormick; José A Munguía-Moreno; Eloisa Ibarra-Sierra; Jaime Escobar-Herrera; Paul F Lambert; Daniel Mendoza-Villanueva; Rosa M Bermudez-Cruz; Patricio Gariglio
Journal:  Virology       Date:  2013-09-27       Impact factor: 3.616

6.  Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.

Authors:  Yi Zheng; Yicheng Yang; Shu Wu; Yongqiang Zhu; Xiaolong Tang; Xiaopeng Liu
Journal:  Bioengineered       Date:  2016-10-18       Impact factor: 3.269

7.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 8.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

Review 9.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 10.  Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.